Adjunctive Doxycycline for Central Nervous System Tuberculosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

August 21, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

December 31, 2027

Conditions
Tuberculosis, MeningealTuberculosis; Meningitis (Etiology)Tuberculosis, Central Nervous SystemTuberculosis; Meningoencephalitis (Etiology)
Interventions
DRUG

Doxycycline

adjunctive doxycycline to standard anti-tuberculous treatment and corticosteroid therapy

DRUG

Placebo

Placebo

DRUG

Anti Tuberculosis Drug

Standard anti-tuberculous therapy

DRUG

Adjunctive corticosteroid

Adjunctive corticosteroids to be dosed at 0.4mg/kg/day of dexamethasone or equivalent for week 1, then 0.3mg/kg/day for week 2, 0.2mg/kg/day for week 3, 0.1mg/kg/day for week 4, then tapered to stop over the next 4 weeks. Other forms of corticosteroids are also acceptable eg. hydrocortisone, methylprednisolone at the equivalent dosage

Trial Locations (5)

119228

RECRUITING

National University Hospital, Singapore

Unknown

NOT_YET_RECRUITING

Adam Malik Hospital, Medan

NOT_YET_RECRUITING

Universitas Sumatera Utara, Medan

NOT_YET_RECRUITING

Sarawak General Hospital, Kuching

RECRUITING

Tan Tock Seng Hospital, Singapore

All Listed Sponsors
collaborator

National Medical Research Council (NMRC), Singapore

OTHER_GOV

lead

National University Hospital, Singapore

OTHER

NCT06446245 - Adjunctive Doxycycline for Central Nervous System Tuberculosis | Biotech Hunter | Biotech Hunter